SCHEMBL3500787

SCHEMBL3500787

CC1(C)OCC(CNO)O1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.56
NAMPT P43490 3/20 0.37
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TMEM97 Q5BJF2 2/20 0.35
SIGMAR1 Q99720 2/20 0.35
CHRM2 P08172 3/20 0.33
CHRM4 P08173 3/20 0.33
CHRM5 P08912 3/20 0.33
CHRM3 P20309 3/20 0.33
CHRM1 P11229 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5990159 1.00 CA2 (0.56) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL6844207 1.00 CA2 (0.56) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL20689800 0.83 CA2 (0.59) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL4423252 0.81 CA2 (0.58) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL12786547 0.81 CA2 (0.58) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL12786551 0.81 CA2 (0.58) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL10433600 0.80 CA2 (0.45) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL6712276 0.80 CA2 (0.38) CA2
SCHEMBL24465140 0.79 CA2 (0.56) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL1760212 0.79 CA2 (0.61) CA2NAMPTALDH1A1NPSR1TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119301106-A Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease 佩特拉制药公司 2025-01-10 CN disclosed
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 EP disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed
US-9163033-B2 Nitrogen-containing heterocyclic compounds and methods of making the same BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2015-10-20 US disclosed
US-20140350246-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA (US) 2014-11-27 US disclosed
US-20120271046-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO 2012-10-25 US disclosed
US-20100113413-A1 MAPK/ERK Kinase Inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-7078438-B2 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY (US) 2006-07-18 US disclosed
US-20050137263-A1 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY, LLC 2005-06-23 US disclosed
US-6891066-B2 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY (US) 2005-05-10 US disclosed
EP-1467965-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS Warner-Lambert Company LLC (US) 2004-10-20 EP disclosed
EP-1467968-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS Warner-Lambert Company LLC (US) 2004-10-20 EP disclosed
US-6770778-B2 MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS PFIZER INC 2004-08-03 US disclosed
US-20040006245-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters REWCASTLE GORDON WILLIAM (NZ) 2004-01-08 US disclosed
US-20030232889-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters WARNET-LAMBERT COMPANY LLC 2003-12-18 US disclosed
WO-2003062191-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 WO disclosed
WO-2003062189-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232889-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters AADAC, EGLN3, HCAR2 CA2 338/4885NAMPT 152/4885ALDH1A1 363/4885
US-20120271046-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME NISCH, HDHD5, DHPS CA2 1946/4885NAMPT 257/4885ALDH1A1 582/4885
US-20050137263-A1 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters PAH, EGLN3, PAOX CA2 311/4885NAMPT 168/4885ALDH1A1 377/4885
US-20040006245-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters HCAR2, EGLN3, AADAC CA2 288/4885NAMPT 161/4885ALDH1A1 436/4885
US-20140350246-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME NISCH, HDHD5, DHPS CA2 1946/4885NAMPT 257/4885ALDH1A1 582/4885
US-20100113413-A1 MAPK/ERK Kinase Inhibitors MAPK1, MAPK6, MAPK4 CA2 3660/4885NAMPT 892/4885ALDH1A1 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.